A new type of immunotherapy known as CAR-NKT cell therapy has demonstrated the ability to kill cancer cells in every late-stage metastatic breast cancer sample tested while also eliminating the immunosuppressive cells that tumours use as shields. The approach is designed as a “one-product-fits-all” treatment that can be manufactured from donated blood stem cells and stored for immediate use.Unlike conventional CAR-T therapies that must be custom-made for each patient, this platform can generate enough cells from a single donation to supply thousands of doses at a significantly lower estimated cost. The engineered cells attack tumours from several angles simultaneously, making it harder for the cancer to adapt and escape.Preclinical work has also shown activity against other solid tumours, including ovarian cancer. With laboratory studies complete, researchers are preparing applications to begin human clinical trials.The development represents a potential shift toward more readily available, off-the-shelf cellular therapies for patients who currently have limited options.
Experimental Off-the-Shelf Immunotherapy Shows Promise Against Aggressive Breast Cancer
Scientists have developed a mass-producible form of immunotherapy that attacks tumours from multiple directions and dismantles their protective defences. Early tests on patient samples proved highly effective, offering hope for a more accessible treatment for hard-to-treat cancers.
